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ABSTRACT
Gastric cancer is the third leading cause of cancer-related mortality worldwide. 
Chemotherapy is frequently used for gastric cancer treatment. Most patients with 
advanced gastric cancer eventually succumb to the disease despite some patients 
responded initially to chemotherapy. Thus, identifying molecular mechanisms 
responsible for cancer relapse following chemotherapy will help design new ways to 
treat gastric cancer. In this study, we revealed that the residual cancer cells following 
treatment with chemotherapeutic reagent cisplatin have elevated expression of 
hedgehog target genes GLI1, GLI2 and PTCH1, suggestive of hedgehog signaling 
activation. We showed that GLI1 knockdown sensitized gastric cancer cells to CDDP 
whereas ectopic GLI1 expression decreased the sensitivity. Further analyses indicate 
elevated GLI1 expression is associated with an increase in tumor sphere formation, 
side population and cell surface markers for putative cancer stem cells. We have 
evidence to support that GLI1 is critical for maintenance of putative cancer stem 
cells through direct regulation of ABCG2. In fact, GLI1 protein was shown to be 
associated with the promoter fragment of ABCG2 through a Gli-binding consensus site 
in gastric cancer cells. Disruption of ABCG2 function, through ectopic expression of 
an ABCG2 dominant negative construct or a specific ABCG2 inhibitor, increased drug 
sensitivity of cancer cells both in culture and in mice. The relevance of our studies to 
gastric cancer patient care is reflected by our discovery that high ABCG2 expression 
was associated with poor survival in the gastric cancer patients who underwent 
chemotherapy. Taken together, we have identified a molecular mechanism by which 
gastric cancer cells gain chemotherapy resistance.
INTRODUCTION
Although gastric cancer is the third leading cause 
of cancer-related death worldwide [1–4], our basic 
understanding of gastric cancer falls behind that of many 
other cancer types. Clinically, gastric cancer is treated by 
surgical resection with chemotherapeutic interventions as 
major options [5]. Even with an increased enrollment rate for 
chemotherapy of gastric cancer, the overall median survival 
remains between 15 to 17 months [6]. Patients initially 
respond to chemotherapy but cancer eventually relapses. 
Therefore, chemotherapy resistance becomes a major barrier 
to achieve effective gastric cancer treatment. Thus, finding 
novel strategies to sensitize cancer cells to chemotherapy 
will significantly improve gastric cancer patient survival.
Chemotherapy in gastric cancer is generally 
used as multimodality treatment, such as perioperative 
and adjuvant chemotherapy [7, 8]. The common 
chemotherapeutical agents for gastric cancer include 
cisplatin (CDDP), 5-fluorouracil (5-FU) or its oral 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 16), pp: 27412-27427
Research Paper
Oncotarget27413www.impactjournals.com/oncotarget
administered derivatives capecitabine and S-1. Common 
combinations include ECF (epirubixin, cisplatin and 
5-FU), 5-FU plus either cisplatin or docetaxel (or 
irinotecan) with radiation [9, 10]. The mechanisms 
underlying chemoresistance in gastric cancer are not 
entirely known, but the following mechanisms have been 
reported: decreased intracellular drug accumulation and/
or increased drug efflux, increased nucleotide excision-
repair activity, evasion of apoptosis, activation of several 
signaling pathways and the existence of putative cancer 
stem cells. Another theory for chemosensitivity is the 
cancer stem cell hypothesis: a small percentage of cancer 
cells, the residual cancer cells or the putative cancer stem 
cells, are resistant to chemotherapy-mediated cell killing, 
and become the source for cancer relapse. If the regulatory 
mechanisms for maintaining this cell population are 
discovered, agents disrupting the mechanisms may be used 
to develop novel strategies to treat gastric cancer.
There are a number of signaling pathways involved 
in regulation of drug resistance, including the hedgehog 
pathway [11–15]. Hedgehog signaling is an important 
pathway for embryonic development, tissue patterning, cell 
differentiation, cancer development and drug resistance 
[16–18]. In the last few years, hedgehog signaling is 
reported in regulation of drug resistance in several types 
of cancer including ovarian, prostate and pancreatic cancer 
[11, 15, 19–21]. In hedgehog signaling active cells, the 
hedgehog ligands (Shh, Ihh or Dhh) bind to PTCH1, 
allowing smoothened to signal to the downstream GLI 
transcription factors, which then turn on the target genes 
[18]. Target genes of hedgehog signaling include GLI1, 
PTCH1 as well as other molecules involved in regulation 
of cancer cell function, such as ABCG2 [22]. ABCG2 is an 
important transportor and functions in maintenance of the 
stem cell population through side population regulation.
In this study, we report a novel mechanism underlying 
drug resistance in gastric cancer. We found that treatment of 
gastric cancer cells with the chemotherapeutical drug CDDP 
often results in elevated hedgehog (Hh) signaling which is 
associated with an increase in putative cancer stem cell 
markers. We further investigated the functional significance 
of Hh signaling and ABCG2 in cultured cells and in mouse 
models. The relevance of our findings to gastric cancer 
patients was further examined in human specimens. 
These findings may lead to novel strategies to improve the 
effectiveness of chemotherapy in gastric cancer.
RESULTS
Expression of Hh target genes following 
chemotherapeutical drug treatment
To delineate the molecular mechanisms underlying 
chemotherapy resistance in gastric cancer, we examined 
molecular changes following treatment with CDDP, the most 
common chemotherapeutical agent [23–25]. Two cancer 
cell lines N87 and AGS were used in our initial studies. We 
predicted that the residual cells with intrinsic drug resistance 
to chemotherapy will survive following drug treatment, and 
the responsible genes will be up-regulated. As a first step, 
we measured the IC50 of CDDP in gastric cell lines from the 
inhibition rate of cell viability by different concentrations of 
CDDP (Figure 1A and 1B). We then treated cells with CDDP 
at the IC50 dose for 48 hr and examined the candidate gene 
expression. Previous studies indicate many candidate genes 
involved in regulation of residual cancer cells or putative 
cancer stem cells, such as Hh, Wnt and Notch signaling 
molecules [26–28]. As shown in Figure 1C, we found that 
target genes for the Hh signaling pathway, GLI1, GLI2 and 
PTCH1, were significantly induced in CDDP-treated N87 
cells. Similar results were also obtained from AGS cells 
(Figure 1D). In contrast, we did not observe significant gene 
expression changes in DKK1, JAG2 or CTGF, molecules 
involved in Wnt, Notch and Hippo/YAP signaling (Figure 
1C and 1D, Supplementary Figure 1).
Like Wnt and Notch signaling, Hh signaling plays 
an important role in embryonic development, and is also 
critical for maintenance of putative cancer stem cells 
or residual cancer cells [26, 29, 30]. We thus examined 
expression of several putative cancer stem cell markers 
[31–38] following CDDP treatment in N87 cells. 
There are a number of factors involved in regulation of 
putative cancer stem cells [39–43]. For example, the side 
population is often enriched in stem cells and cancer 
stem cells, and ABCG2 is the major gene regulating side 
population [44]. Sox2 is another important factor involved 
in regulation of putative cancer stem cells [45]. Through 
real-time PCR analysis, we found high expression of 
ABCG2 following drug treatment (Figure 1C). This 
phenomenon did not appear to be cell line specific because 
similar results were also observed in AGS cells (Figure 
1D). In contrast, SOX2 expression was not significantly 
changed (Figure 1C and 1D).
These results indicate that elevated Hh signaling 
may be responsible for maintenance of residual cancer 
cells (or putative cancer stem cells or tumor initiating 
cells) following chemotherapeutic drug treatment in 
gastric cancer.
Significance of GLI1 expression for intrinsic 
drug resistance in gastric cancer cells
To evaluate the functional relevance of Hh signaling 
for the intrinsic drug resistance in N87 and AGS cells, we 
first knocked down GLI1 expression by expressing GLI1 
shRNAs in both cell lines, and then determined the IC50 
for CDDP. We found that down-regulation of GLI1 in 
N87 cells (Figure 2A) reduced the IC50 by nearly half 
(Figure 2B). The IC50 value was also reduced by GLI1 
knockdown in AGS cells (Figure 2C and 2D). Additional 
experiments in IC50 measurement and tumor sphere 
formation indicate that knocking down both GLI1 and GLI2 
has similar effect as GLI1 knockdown (Supplementary 
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Figure 2 for IC50 value, and Supplementary Figure 3 for 
tumor sphere formation), suggesting that the feed-forward 
loop exerted by GLI1 is the major factor for regulation of 
putative cancer stem cells. Thus, GLI1, the focus for the 
rest of our study, appears to be critical for drug resistance 
in gastric cancer cells.
Furthermore, we determined whether elevated Hh 
signaling is sufficient to drive drug resistance in gastric 
cancer cells by ectopic expression of GLI1 in N87 and 
AGS cells, and examining their IC50 values for CDDP. 
We discovered that ectopic GLI1 expression in both N87 
and AGS cells significantly increased the IC50 value 
(Figure 2E-2H).
Taken together, we found that the GLI1 expression 
level is highly associated with chemosensitivity in gastric 
cancer cells. While down-regulation of GLI1 decreases 
Figure 1: Elevated hedgehog signaling following CDDP treatment in gastric cancer cells. (A) The inhibition rate of cell 
viability by different concentrations of CDDP in N87 cells were determined by chemosensitivity assay (see Methods), and the IC50 was 
calculated from this experiment. Cells were treated with increasing concentrations of CDDP (5, 10, 25, 50, 100 μM) for 48 hr. (B) The 
rate of cell viability inhibition by CDDP in AGS cells were also determined by chemosensitivity assay (see Methods), and we calculated 
the IC50 from this experiment. (C) The transcript levels of GLI1, GLI2, PTCH1, DKK1, JAG2, CTGF, SOX2 and ABCG2 in N87 cells 
after treatment with 25 μM CDDP for 48 hr. (D) The transcript levels of above genes in AGS cells after 10 μM CDDP for 48 hr. Data are 
represents as mean ± SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.
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the IC50, ectopic expression of GLI1 increases the 
CDDP IC50.
Regulation of the putative cancer stem cell 
population by GLI1
Previous studies have revealed heterogeneous cell 
populations even within the established cell lines [31–38], 
and our experiments with CDDP treatment studies also 
suggest that a subset of cells (e.g. putative cancer stem 
cells) are more resistant to drug treatment, and that GLI1 
may play an important role in maintenance of this cell 
population. To directly test the role of GLI1 for putative 
cancer stem cell maintenance, we detected the putative 
cancer stem cell population in gastric cancer cells using 
three methods.
First, we measured tumor sphere forming efficiency 
from N87 cells with GLI1 shRNAs, ectopic GLI1 
expression or the control cells. Tumor sphere formation 
efficiency is a known biological readout of cancer stem 
cells [46]. We found that GLI1 knockdown significantly 
reduced the size of tumor spheres (Figure 3A). GLI1 
shRNA expression also reduced the tumor sphere forming 
efficiency (Figure 3A, with the control ~38 spheres /2000 
cells and Gli1 knockdown cells 29 spheres/ 2000 cells, P = 
0.032). Conversely, ectopic expression of GLI1 increased 
Figure 2: GLI1 expression is required and sufficient for intrinsic drug resistance in gastric cancer cells. (A) GLI1 transcript 
level and the protein level in N87/shCtrl and N87/shGLI1 cells as determined by real-time PCR and Western blot analysis, respectively. 
(B) IC50 dose of CDDP in N87/shCtrl and N87/shGLI1 cells determined by chemosensitivity assay. (C) GLI1 transcript and protein levels 
in AGS/shCtrl and AGS/shGLI1 cells. (D) The CDDP IC50 dose in AGS/shGLI1 cells compared with AGS/shCtrl cells. (E, F) The effect 
of ectopic Gli1 expression on the IC50 of CDDP in N87 cell. (E) shows GLI1 transcript (upper) and protein (low) levels in N87 with or 
without ectopic GLI1 expression (pLNCX indicates the vector control, and pLNCX-Gli1 indicates ectopic Gli1 expression). (F) shows the 
IC50 values from pLNCX and pLNCX-Gli1 N87 cells. (G, H) The effect of ectopic Gli1 expression on the IC50 value of CDDP in AGS 
cells. (G) shows GLI1 transcript (upper) and protein (low) levels in AGS cells with pLNCX as the vector control and pLNCX/GLI1 as the 
ectopic Gli1 expression. (H) shows the IC50 values from pLNCX and pLNCX/GLI1. Means ± SD from three independent experiments are 
shown. * P < 0.05, ** P < 0.01, *** P < 0.001.
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the tumor sphere forming efficiency (Figure 3C, with the 
control ~32.5 spheres/2000 cells and GLI1 expressing 
cells 80 spheres/ 2000 cells, P = 0.034). It thus appears 
that high GLI1 expression increases the tumor sphere 
forming efficiency.
Second, we also detected side population of cancer 
cells after GLI1 alteration. Side population is a functional 
assay for the transporter ABCG2, and is a well-known 
readout for stem cells and putative cancer stem cells [47–
49]. We found that GLI1 shRNA reduced the side population 
by 40% (Figure 3B) whereas ectopic GLI1 expression 
increased the side population by 100% (Figure 3D).
Third, we also detected cell surface marker 
expression following alteration of GLI1 levels. Since 
there are no consensus cell surface markers for putative 
cancer stem cells in gastric cancer, we examined changes 
in the following markers: CD24, CD33, CD44, CD90 
and CD133 that are reported in the literature [31–38]. 
We did not see significant changes in CD24, CD44 and 
CD33 in our experiments. However, we found that GLI1 
knockdown significantly reduced expression of CD90 
and CD133 (Supplementary Figure 4A/B) whereas 
ectopic GLI1 expression increased expression of CD90 
(Supplementary Figure 4C/D). Although CD44 was 
reduced by GLI1 shRNAs and was reportedly regulated by 
hedgehog signaling [50], the decrease in our experiments 
did not reach statistical significance.
Figure 3: GLI1 regulates the putative cancer stem cell population in N87 cells. (A) Representative images and statistical graph 
of N87/shCtrl and N87/shGLI1 cells grown as tumor spheres. (B) Side population in N87/shCtrl and N87/shGLI1 cells was measured by 
flow cytometry. Representative flow cytometric analysis was shown. (C) Representative images of spheres from N87/pLNCX and N87/
pLNCX/GLI1 cells. (D) The percentage of side population in N87/pLNCX/GLI1 cell and the control cells. All data are means ± SD of three 
independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.
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Taken all the data together, we concluded that GLI1 
expression is an important factor for maintenance of the 
putative cancer stem cell population as indicated by tumor 
sphere forming efficiency and side population. While 
GLI1 knocking down reduces the putative cancer stem 
cell population, ectopic expression of GLI1 increases this 
population.
The role of ABCG2 in drug sensitivity regulation 
in gastric cancer cells
Because ABCG2 is responsible for exclusion of 
Hoechst 33342 dye and the subsequent side population, we 
tested whether GLI1 directly regulate ABCG2 expression. 
Through real-time PCR analysis, we found that while 
GLI1 shRNAs significantly reduced ABCG2 expression by 
half, ectopic GLI1 expression induced ABCG2 transcript 
by 100% (Figure 4A). Similarly, treatment with CDDP 
increased expression of ABCG2 (Figure 1C and 1D) and 
the side population (Figure 4B).
After promoter analysis, we discovered a GLI1-
binding consensus site [18] in the promoter of ABCG2 
(Supplementary Figure 5C), suggesting that ABCG2 may 
be a transcriptional target of GLI1 molecules. We performed 
ChIP analysis [51] following ectopic expression of GLI1 
in N87 and AGS cells (Supplementary Figure 5A and 
5B). Supplementary Figure 5C showed the 9 base pairs 
sequence of the potential GLI1 binding site within the 
ABCG2 promoter. Our data indicate that ectopically 
expressed GLI1 protein (with MYC tag) can be pulled 
down with the ABCG2 promoter region encompassing 
the GLI1 binding site (Supplementary Figure 5D and 
5E) whereas the control IgG does not pull down the 
fragment. Similarly, MYC antibodies did not pull down 
the fragment in cells without ectopic GLI1 expression. 
These results suggest that GLI1 may directly regulate 
ABCG2 expression by transcriptional regulation, which 
is consistent with a previous report in lymphomas [52].
Next, we evaluated the functional relevance of 
ABCG2 for regulating drug sensitivity. We used two 
Figure 4: Regulation of ABCG2 by GLI1. (A) The ABCG2 transcript level in N87/shCtrl and N87/shGLI1 cells (left panel), N87/
pLNCX and N87/pLNCX/GLI1 cells (right panel) as detected by real-time PCR. (B) Representative side population analysis and statistical 
graph of side population in N87 cells treated with 25 μM CDDP in comparison with control cells. Means ± SD are shown. ** P < 0.01.
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methods to reduce ABCG2 function. First, we used a 
truncated form of ABCG2, which has a dominant negative 
effect on the endogenous ABCG2 gene function [53], and 
found that ectopic expression of this truncated form of 
ABCG2 reduced the IC50 of CDDP by half (Figure 5A), 
which was associated with reduced side population (Figure 
5B and Supplementary Figure 6A) and a decrease in CD90 
expression (Supplementary Figure 6B). Similarly, when 
an ABCG2 inhibitor FTC [54] was used, we observed 
a significant reduction in the IC50 (Figure 5C), sphere 
formation (Figure 5D) and side population (Figure 5E, 
Supplementary Figure 6C). Conversely, we found that 
overexpression of ABCG2 increased the IC50 for CDDP 
(Figure 6A), which was associated with an increase in 
side population (Figure 6B), sphere formation (Figure 
6C and Supplementary Figure 6D) and CD90 expression 
(Supplementary Figure 6E).
The effect of ectopic ABCG2 expression on the 
IC50 of CDDP was very similar to that GLI1 expression, 
suggesting that ABCG2 may be the major mediator for 
regulating drug sensitivity in gastric cancer. In consistent 
with our hypothesis, ectopic expression of ABCG2 had 
no significant effects on expression of GLI1, GLI2 and 
PTCH1 in both N87 and AGS cells (Supplementary Figure 
7), further confirming that hedgehog signaling is upstream 
of ABCG2 in our experiment system.
Therapeutic effects of CDDP in ectopic 
expression of GLI1 xenograft model
To determine the relevance of our in vitro studies 
to therapeutic implication, we tested the effects of CDDP 
on the subcutaneous mouse model using N87 cells with 
alterations in GLI1 and ABCG2. GLI1 was ectopically 
expressed in N87/pLNCX/GLI1 cells while GLI1 
expression was knocked down in N87/shGLI1 cells. A 
truncated form of ABCG2 was expressed in N87/pBabe/
TM5-6 cells. As shown in Figure 7A and 7B, CDDP 
treatment reduced the tumor significantly in the N87 
control group. In contrast, ectopic GLI1 expression in N87 
cells did not respond to CDDP treatment whereas GLI1 
shRNA expression sensitized tumors to CDDP treatment. 
Blockage of ABCG2 function, via ectopic expression of a 
dominant negative construct ABCG2/TM5-6, made N87 
Figure 5: Regulation of drug sensitivity by ABCG2. (A) Effects of ABCG2-TM5-6, the truncated form of ABCG2 on drug 
sensitivity. ABCG2-TM5-6 was detected by the Myc-tag in Western blot analysis (left panel). The IC50 for CDDP in these two groups of 
cells were shown in the right panel. (B) Statistical graph of side population distribution in N87/pBabe and N87/pBabe/TM5-6 cells. (C) The 
IC50 of CDDP in N87 cells with or without FTC (10 μM). (D) Representative images and statistical graph of spheres in N87 cells treated or 
untreated with FTC. (E) Statistical graph of side population in N87 cells with or without FTC. The results are means of three independent 
experiments ± SD. * P < 0.05, ** P < 0.01.
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gastric cancer cells more sensitive to CDDP treatment 
(Figure 7B). Tumors formed from the cells expressing 
shGLI1 or TM5-6 reduced the tumor size significantly 
following CDDP treatment (Figure 7D and 7E). In 
contrast, tumors formed from the cells with ectopic GLI1 
expression were not significantly affected by CDDP (in 
compared with the N87 control group, Figure 7C). These 
results are consistent with the in vitro studies, further 
confirming that the levels of GLI1 and ABCG2 expression 
determine the sensitivity of gastric cancer cells to CDDP 
treatment.
Higher ABCG2 expression in gastric cancer 
patients with poor prognosis
We went further to find the relevance of our data to 
gastric cancer patients by correlating ABCG2 expression 
in the tumor with the survival of patients who underwent 
chemotherapy using CDDP. The expression level of 
ABCG2 was analyzed by immunohistochemistry in 
180 cases of gastric cancer patients who underwent 
chemotherapy. According to our criteria (see Materials 
and Methods), 62% (111/180) of gastric cancer specimens 
were positively stained with anti-ABCG2 antibodies 
(Figure 8A). We found that positivity of ABCG2 staining 
was significantly correlated with clinicopathological 
parameters. As shown in Table 1, the presence of ABCG2 
was higher in poorly differentiated gastric cancer 
specimens in comparison with well-differentiated ones 
(Figure 8B, P = 0.0005). There was no difference in the 
correlation between ABCG2 expression and gender, age, 
tumor size and tumor location (see Table 1 for details). 
Among these 180 gastric cancer patients, 170 cases were 
available with the follow-up information. As Figure 8C 
shown, higher ABCG2 expression in gastric cancer was 
correlated with a shorter overall survival, indicating that 
high ABCG2 expression in the tumor predicts a poor 
outcome in chemotherapy in gastric cancer patients.
Because there are no GLI1 antibodies suitable for 
immunohistochemistry in paraffin-embedded tissues, 
we took the advantage of the CTGA data to test whether 
higher GLI1 transcript level is correlated with cancer 
relapse or patient survival in those patients who underwent 
chemotherapy. In a cohort of 415 cancer specimens, we 
found that 7 out of 12 (>50%) patients with high GLI1 
transcript had relapsed cancer whereas 102 out of 310 
patients with low GLI1 expression had relapsed cancer. 
In addition, patients with high Gli1 expression had worse 
Figure 6: ABCG2 overexpression increases drug resistance. (A) The ABCG2 transcript level in N87/pSIN4 and N87/pSIN4/
ABCG2 cells was detected by real-time PCR (left panel). The IC50 of CDDP was shown in the right panel. (B) Statistical graph of side 
population analysis in N87/pSIN4 and N87/pSIN4/ABCG2 cells. (C) Representative images of spheres (left two panels) and statistical 
graph of tumor spheres in N87/pSIN4 and N87/pSIN4/ABCG2 cells. Means ± SD are shown. * P < 0.05, *** P < 0.001.
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disease-free survival (Supplementary Figure 9). These 
results suggest that the GLI1-ABCG2 signaling axis is 
associated with poor outcomes of the gastric cancer patients.
From all these data, we conclude that activation 
of Hh signaling, through regulation of ABCG2, plays 
an important role in regulation of drug sensitivity in 
gastric cancer. We predict that the novel strategies aimed 
at reducing GLI1 expression or interrupting ABCG2 
function, together with CDDP-based chemotherapy, 
should improve the survival of gastric cancer patients.
DISCUSSION
Gastric cancer remains a major contributor for 
cancer-related mortality. Most patients are diagnosed 
with advanced disease where the five-year survival rate is 
very low (< 5%) [1]. Although the regulatory mechanisms 
for chemotherapy resistance in gastric cancer have been 
reported in the last 10 years [55], very little data have been 
linked the mechanisms to patient survival. Our results 
indicate that the GLI1-mediated regulation of ABCG2 
is an important mechanism responsible for maintenance 
of the residual cancer cells (or putative cancer stem 
cells) in gastric cancer following treatment with CDDP, 
a major chemotherapeutical drug. We have data to show 
that knocking down GLI1 (Figure 2 and Figure 3) or 
inhibiting ABCG2 functions (Figure 5), sensitizes cancer 
cells to chemotherapy in cultured cells (Figure 2-6) and in 
mice (Figure 7). More importantly, we have shown that 
higher GLI1/ ABCG2 expression is associated with poor 
survival of gastric cancer patients who underwent CDDP-
based chemotherapy (Figure 8 and Supplementary Figure 
Figure 7: CDDP sensitivity in mouse models. (A) Photographs of tumor xenografts derived from N87, N87/pLNCX/GLI1, N87/
shGLI1 or N87/pBabe/TM5-6 in NSG mice treated with PBS (top) or CDDP treatment (bottom). (B) Tumor weights shrink percentage 
after CDDP treatment compared with PBS control in four different xenografts groups. (C) The growth curves of tumor xenografts in mice 
during CDDP treatment in N87 and N87/pLNCX/GLI1 groups. (D) The tumor growth in N87/shGLI1 group and the N87 control group 
during CDDP treatment. (E) Tumor growth curves in N87 and N87/pBabe/TM5-6 groups. Means ± SD are shown. * P < 0.05, ** P < 0.01.
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9). Since inhibitors for GLI1 and ABCG2 are already 
available, we predict that these agents, together with 
CDDP-based chemotherapy, will improve gastric cancer 
patient survival.
Like Wnt and Notch signaling pathways, Hh 
signaling is known to be a critical regulator for embryonic 
development, and is involved in maintenance of the cancer 
cell stemness in a number of cancer types [18, 26, 29, 30, 
56]. There are several reports on association of Hh signaling 
with drug resistance [13, 56, 57], but the molecular link is 
often not known. Yoon et al reported a link between Hh 
signaling and CD44 expression in a number of cell lines 
through sphere formation studies, which was shown to be 
associated with cisplatin resistance in gastric cancer [50]. 
While we have confirmed regulation of CD44 by GLI1 
expression, we found that GLI1 affects ABCG2 more 
dramatically, with little effects on CD44 (Supplementary 
Figure 4). Furthermore, we demonstrated that inhibition 
of ABCG2 by expressing a truncated ABCG2 molecule or 
addition of a specific inhibitor, sensitizes cancer cells to 
CDDP treatment (Figure 5). We found that the ligands, Shh 
and Ihh, were not significantly altered by CDDP in N87 and 
AGS cells (Supplementary Figure 8), suggesting that up-
regulation of GLI1 in these cells was not caused by ligand-
dependent signaling. This implies that the SMO inhibitors, 
with two already approved by FDA for basal cell carcinoma 
treatment [58], will not be effective in sensitizing gastric 
cancer cells to chemotherapy. It will be interesting, though, to 
reveal the molecule mechanisms by which GLI1 expression 
is induced in cancer cells with intrinsic tolerance of CDDP, 
which may provide additional strategies to sensitize gastric 
cancer cells to chemotherapy. Targeting ABCG2 will be a 
Figure 8: Correlation of ABCG2 expression in gastric cancer with tumor differentiation and patient survival. (A) 
Representative images of immunohistochemical staining of ABCG2 in gastric cancer specimens. Original magnification: 40× and 400×. 
(B) Staining of ABCG2 and correlation with tumor differentiation (P = 0.0005). (C) Kaplan-Meier analysis of the significance of ABCG2 
in predicting gastric cancer patient overall survival. P = 0.0057 by log rank test.
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more feasible strategy to improve the sensitivity of gastric 
cancer cells to chemotherapy. Although ABCG2 is known 
to be responsible for transporting several types of small 
molecules, such as ions, dyes and some chemotherapeutical 
drugs, CDDP transport in and out of cells is not affected by 
ABCG2 [59, 60], further confirming that ABCG2 expression 
may represent a subset of cell population (side population) 
with cancer cell stemness.
MATERIALS AND METHODS
Cell culture
Human gastric cancer cell lines AGS and N87, and 
HEK293T were purchased from ATCC. Gastric cancer 
cells were maintained in RPMI-1640, while HEK293T 
cells were cultured in DMEM, supplemented with 10% 
FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 
37°C in a humidified environment containing 5% CO2. 
Exponentially growing cells were used for experiments.
Cell viability and chemosensitivity assay
Cells (2000/well for AGS, 4000/well for N87) were 
seeded into 96-well plates and stained at the indicated 
time point using alamarBlue (Thermo scientific, FL, 
USA) according to the manufacturer’s instructions. The 
optical density measured at 530/590 nm was used as an 
indicator of cell viability. For chemosensitivity assay, the 
medium was replaced by fresh medium with or without 






negative (n = 69) positive (n = 111)
Gender
 Male 46 77 0.7047
 Female 23 34
Age (years)
 ≤ 60 35 41 0.0686
 >60 34 70
Tumor size (cm)
 ≤ 5 36 55 0.7321
 >5 33 56
Location
 Distal third 41 59 0.4107
 Middle third, proximal 
third 28 52
Differentiation
 Poorly, undifferentiated 19 60 0.0005
 Well, moderatelly 50 51
Local invasion
 T1, T2 9 16 0.7960
 T3, T4 60 95
Lymph node metastasis
 No 19 27 0.6310
 Yes 50 84
TNM stage
 I, II 28 41 0.6250
 III, IV 41 70
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various concentrations of Cisplatin (CDDP, Calbiochem, 
CA, USA) (5, 10, 25, 50, 100 μM). Cell viability assay 
was performed after 48 hrs of treatment [61–63]. Six 
wells were counted for each drug concentration and at 
least three independent experiments were performed. 
The half maximal inhibitory concentration (IC50) value 
was defined as the concentration that resulted in a 50% 
reduction in cell growth compared with growth of the 
control.
Plasmids construction, lentiviral and retroviral 
infection
The plasmid pLNCX/GLI1 (with a Myc tag) was 
previously constructed in our laboratory [51] and pLKO.1/
shGLI1 and their corresponding control plasmid pLKO.1/
shCtrl were from the Broad Institute. Expression plasmid 
pSIN4/ABCG2 was purchased from Addgene (#25983). 
The ABCG2/TM5-6 plasmid was kindly provided by Dr. 
Jian-ting Zhang at Indiana University School of Medicine, 
and subcloned into pBabe using EcoRI and BamHI to 
obtain pBabe/TM5-6 (with Myc tag) [53].
To generate GLI1 knockdown, ABCG2 and TM5-
6 overexpression cells, AGS and N87 cells were infected 
with lentivirus containing pLKO.1/shGLI1, pSIN4/
ABCG2 and pBabe/TM5-6, respectively. Lentiviral 
packaging plasmids PRRE, RSV/REV and CMVG were 
co-transfected into HEK293T cells using Lipofectamine 
3000 (Invitrogen, Carlsbad, CA, USA) for virus 
production and infection as previously described [64]. 
Twenty-four hours after infection, cells were selected with 
1 μg/ml puromycin (Sigma, St Louis, MO, USA) or 1 mg/
ml G418 (Invitrogen).
Reverse transcriptase and real-time PCR
Total RNA was isolated from cells using TRIzol 
reagent (Sigma) according to the manufacturer’s 
instructions. One microgram of total RNA was reverse 
transcribed into cDNAs using the First-Strand Synthesis 
Kit (Roche, Indianapolis, IN, USA). The abundance of 
transcripts in the cDNA samples was measured by real-
time PCR with specific probes as instructed from the 
provider and previously described [65, 66]. All probes 
for real-time PCR were purchased from the Applied 
Biosystems.
Western blot analysis
Cells were lysed in cell lysis buffer (50 mM Hepes, 
pH 7.4, 2 mM EDTA, 100 mM NaCl, 1% Glycerol, 1% 
Triton X-100) containing protease and phosphatase 
inhibitors. After separation by SDS-polyacrylamide 
gel electrophoresis and protein transfer onto PVDF 
membrane. Antibodies were used to incubate with the 
membrane [Rabbit anti-GLI1 antibody diluted at 1:1000 
(from the Cell Signaling Technology, MA, USA); mouse 
anti-Myc 9B11 antibody (diluted at 1:1000, the Cell 
Signaling Technology); mouse anti-β actin antibody 
(diluted at 1:10000, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and goat anti-rabbit-HRP/goat anti-
mouse-HRP (diluted at 1:10000, Thermo scientific)]. 
Detection was performed with ECL Western blotting 
detection kit (Thermo scientific) as described previously 
[64, 66].
Flow cytometry analyses
Single cells were dissociated using Accutase® 
(Gibco, CA, USA) and re-suspended in PBS containing 
10% FBS. The cells were incubated with fluorescence-
conjugated antibody against human CD24, CD33, 
CD44, CD90, CD133 and ABCG2 (all from Biolegend, 
CA, USA) for 30min at 4°C. After washing, cells were 
analyzed on FACSCalibur or FACSCanto II (Beckton 
Dickinson, Franklin Lakes, NJ, USA) [66].
For side population assay, single cells were re-
suspended at 1 × 106/ml in DMEM with 2% FBS and 
10 mM HEPES, stained with Hoechst 33342 dye (final 
concentration 5 μg/ml, Invitrogen) and incubated at 
37°C for 90 min with shaking. The cells were washed 
with ice-cold HBSS with 2% FBS and 10 mM HEPES, 
spined down at 4°C and re-suspended in ice-cold HBSS 
containing 2 μg/ml propidium iodide (PI, Invitrogen). An 
aliquot of cells was used as a negative control by adding 
ABC transporter inhibitor fumitremorgin C (FTC, 10 μM, 
Calbiochem) and incubated at 37°C for 30 min before 
addition of Hoechst 33342.
Sphere formation assay
Cells were re-suspended in sphere formation 
medium (Neural Basal medium with 1× B-27, 20 ng/ml 
of EGF, 10 ng/ml of βFGF and 5 μg/ml of heparin), and 
plated on ultralow attachment 24-well plates with 2000 
cells each well (Corning, Lowell, MA, USA) as described 
previously [67]. Sphere formation medium was changed 
every other day. After 7 days, spheres were counted and 
taken photos, or cells were dissociated with Accutase® 
and used for other experiments. The sphere forming 
efficiency was calculated by counting the number of 
spheres formed from 2000 cells.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed as previously described 
[51]. In brief, cells at 80% confluence were cross-linked 
with formaldehyde (Sigma) at room temperature for 
15 min. Formaldehyde was neutralized by addition of 
125 mM glycine for 5 min. The cells were collected by 
centrifugation and rinsed in cold phosphate-buffered 
saline. The cell pellets were collected by centrifugation 
and then re-suspended in sonication buffer (1% SDS, 10 
mM EDTA, 50 mM Tris-HCl, pH 8.1, 0.5 mM PMSF, 
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and 100 ng of leupeptin and aprotinin/ml) and incubated 
on ice for 20 min. The samples were sonicated on ice 
with an Ultrasonics sonicator at setting 10 for 20-second 
pulses to yield an average length of 500-1000 bp for 
genomic DNA. The chromatin solution was pre-cleared 
with the addition of protein A/G plus agarose beads 
(from the Santa Cruz Biotechnology Inc.) for 30 min 
at 4°C. Prior to use, the protein A/G plus agarose beads 
were blocked with sheared herring sperm DNA (1 μg/
μl) and bovine serum albumin (1 μg/μl) for at least 4 hr 
at 4°C. 10% of the supernatant was saved as total input, 
and the rest was immunoprecipitated with 5 μg of normal 
anti-mouse IgG (Biolegend), 5 μg of Myc-tag mouse 
monoclonal antibody (Cell signaling technology) or 5 μg 
of anti-Histone H3 polyclonal antibody (Biolegend) at 
4°C overnight, and then incubated with protein A/G plus 
agarose beads for 1 hr. Immunoprecipitates were washed 
twice in TE buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA, 
1 mM PMSF), once with Low Salt Wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl, pH 
8.0, 150 mM NaCl, 1 mM PMSF), twice with High Salt 
Wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
20 mM Tris-Cl, pH 8.0, 500 mM NaCl, 1 mM PMSF), 
once with LiCl Wash buffer (0.25 M LiCl, 1% NP-40, 
1% Sodium deoxycholate, 1 mM EDTA, 10 mM Tris-
Cl, pH 8.0, 1 mM PMSF) and three times in TE buffer. 
Immunoprecipitates were eluted in Elution buffer (50 mM 
Tris-Cl, pH 8.0, 10 mM EDTA, 1% SDS, 200 mM NaCl) 
and incubated at 65°C for 30 min. DNA was purified by 
extraction with phenol/chloroform and precipitated with 
1/10 volume of 3 M NaOAc (pH 5.3) and 2.5 volumes of 
ethanol. The DNA fragment was amplified by PCR using 
primers flanking the promoter region 1000 bp upstream. 
Primers used to PCR-amplify the ABCG2 gene chromatin 
were 5’-ATCCCATTCACCAGAAACCA-3’ and 5’–
CGAACGGAATGAACCAGAGT-3’ resulting in a product 
size of 205 bp. Primers used to PCR-amplify 18s as an 
internal control were 5’-CAGCCACCCGAGATTGAGC-3’ 
and 5’-TAGTAGCGACGGGCGGTGTG-3’ resulting in a 
product size of 252 bp.
Tumor xenografts and anticancer chemotherapy 
in vivo
All animal procedures were performed in 
accordance with a protocol approved by the Institutional 
Animal Care and Use Committee in Indiana University 
(Indianapolis, IN). To generate subcutaneous tumors, 
5 × 106 cells were re-suspended in 100 μl PBS and 
subcutaneously injected into NOD scid gamma (NSG) 
mice. Tumor volume (volume = 0.5 × length × width2) 
was measured with a caliper twice a week. When tumors 
reached 80-100 mm3 (as day 0 in this study), mice were 
injected intraperitoneally (i.p.) once a week with CDDP (4 
mg/kg) or vehicle (PBS) control group for two weeks. On 
day 21, mice were sacrificed, and tumor xenografts were 
removed, weighted and fixed in 10% buffered formalin for 
further analysis.
Immunohistochemistry (IHC)
Two ninety-dot tissue arrays were purchased from 
Shanghai Outdo Biotech Company (Shanghai, China). 
Formalin-fixed, paraffin-embedded sections were 
deparaffinized by xylene, rehydrated in ethanol and boiled 
in 10 mM citrate buffer (pH 6.0) for 30 min for antigen 
retrieval. Endogenous peroxidase was blocked by 3% H2O2 
for 10 min for immunoperoxidase labeling. Sections were 
then incubated at 4°C overnight with primary antibodies 
against rabbit anti-ABCG2 (1:100, Abcam, Cambridge, 
UK). Incubation with corresponding secondary antibody 
(ImmPRESS universal peroxidase reagent, Vector Lab, 
CA, USA) and the peroxidase-antoperoxidase complex 
was visualized by DAB kit (ImmPACT DAB Peroxidase 
Substrate, Vector Lab), as previously described [68]. Two 
individuals (B.Y. and J.X.), who had no prior knowledge 
of the clinical pathologic data of the patients, examined 
the stained sections independently. Positive membrane 
ABCG2 staining was assessed by the intensity of stained 
cells and determined in two categories (negative and 
positive). The staining intensity was classified from 0 to 
3+ as follows: 0, no staining; 1+, < 25% of the section was 
stained; 2+, 26% - 50% of the section was stained; 3+, > 
50% of the section was stained. Scores of 1+, 2+ and 3+ 
were considered to be positive.
Statistical analysis
Data are presented as mean ± SD. from at least three 
independent experiments. IC50 values of CDDP were 
calculated with the GraphPad Prism software. Survival 
data were analyzed using the Kaplan-Meier method with a 
log-rank test for comparison of survival curves. Statistical 
comparisons between two groups were performed using a 
two-tail unpaired t-test or the chi-square test, with P values 
of < 0.05 indicating statistically significant difference.
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